According to the Institute of Medicine, needs more resources to track the safety of drugs, once they are approved and marketed. The Institute’s report indicates that an imbalance exists between the resources devoted to the pre-approval process for a drug and the resources available to follow drugs after they receive FDA approval. The FDA recognizes that it must do more to improve drug safety. Some recommendations in the report of the Institute of Medicine include a five-year safety review of drugs after they are put on the market and restricted advertising for new drugs.
Comments are closed.